ARCTOS medical

Bern, Switzerland Founded: 2018 • Age: 8 yrs Acquired By Novartis
Optogenetic therapies for retinal degenerative diseases are developed.
Annual revenue - Latest available
Total funding - Funding intelligence
Employees - Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 10 Brand Intelligence

About ARCTOS medical

ARCTOS medical is a company based in Bern (Switzerland) founded in 2018 was acquired by Novartis in September 2021. ARCTOS medical operates in a competitive market with competitors including EyePoint Pharmaceuticals, Rezolute, Molecular Partners, Aviceda Therapeutics and IVERIC bio, among others.

  • Headquarter Bern, Switzerland
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
Operational Areas
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Latest Funding Round
    Not available
  • Investors
  • Employee Count
    Not available
  • Acquired by
    Novartis

    (Sep 21, 2021)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of ARCTOS medical

Premium access

Detailed funding history for ARCTOS medical

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investors in ARCTOS medical

ARCTOS medical has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Novartis.

All
Institutional
Investor Description Founded Year Domain Location
R&D focused on manufacturing of drugs for multiple therapeutic areas
Locked Locked Locked
Premium access

Investor details for ARCTOS medical

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by ARCTOS medical

Investments
Premium access

Investment portfolio details for ARCTOS medical

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - ARCTOS medical

Premium access

Detailed financials for ARCTOS medical

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Arctos Medical Comparisons

ARCTOS medical Primary company
Description
Optogenetic therapies for retinal degenerative diseases are ...
Location
Bern, Switzerland
Founded Year
2018
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for ARCTOS medical

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of ARCTOS medical

ARCTOS medical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as EyePoint Pharmaceuticals, Rezolute, Molecular Partners, Aviceda Therapeutics and IVERIC bio, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Small molecule therapeutics for ophthalmic disorders are developed.
Locked Locked Locked
Therapies for metabolic and orphan diseases are developed by Rezolute.
Locked Locked Locked
Therapeutic solutions for diseases are developed using DARPin technology.
Locked Locked Locked
Biotherapeutics for glycol-immune diseases are developed across multiple therapeutic areas.
Locked Locked Locked
Gene therapy solutions for retinal diseases are developed.
Locked Locked Locked
Therapies for ophthalmological diseases are developed to restore vision.
Premium access

Detailed competitors of ARCTOS medical

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Arctos Medical

Premium access

Complete news archive for ARCTOS medical

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about ARCTOS medical

ARCTOS medical was founded in 2018.

ARCTOS medical is headquartered in Bern, Switzerland. It is registered at Bern, Bern, Switzerland.

ARCTOS medical was founded in 2018 in Bern, Switzerland, within the biotechnology sector. Optogenetic therapies targeting retinal degenerative diseases are developed using adeno-associated virus gene therapy. Replacement photoreceptors incorporating optogenes are designed to activate specific cells in the retina. Applications focus on addressing blindness linked to conditions such as retinitis pigmentosa and age-related macular degeneration. Operations center on preclinical and clinical advancements in gene-based vision restoration.

ARCTOS medical's top competitors include EyePoint Pharmaceuticals, Rezolute and Molecular Partners.

ARCTOS medical has 1 investor. Key investors include Novartis.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available